Literature DB >> 30944980

Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis.

Sara Mariotto1, Alberto Gajofatto2, Luigi Zuliani3, Marco Zoccarato4, Matteo Gastaldi5, Diego Franciotta5, Gaetano Cantalupo6, Francesca Piardi7, Alberto Polo8, Daniela Alberti2, Stefano Sartori9, Gianluigi Zanusso2, Luigi Agrò10, Rita Demurtas10, GianPietro Sechi10, Elia Sechi10, Salvatore Monaco2, Sergio Ferrari2.   

Abstract

Circulating and cerebrospinal fluid (CSF) neurofilament light chain (NfL) levels represent a reliable indicator of disease activity and axonal damage in different neuroinflammatory conditions. Recently, high CSF NfL levels have been detected in active autoimmune encephalitis, as opposed to significant lower levels after clinical improvement. The aim of the present study was to evaluate serum and CSF NfL concentration in patients with autoimmune encephalitis and to analyse the association between NfL levels and clinical, MRI, and CSF data. We retrospectively included 25 patients with neurological syndromes associated with autoantibodies to neuronal cell surface antigens and we collected clinical, MRI, CSF, and follow-up data. Using an ultrasensitive method (Simoa, Quanterix), we measured NfL levels in serum and CSF samples of all patients and in 25 sera of healthy controls. Serum NfL levels were higher in all cases, including 20 patients with inflammatory MRI/CSF features and 5 non-inflammatory cases (median 16.9 pg/ml, range 4.5-90) than in controls (median 6.9 pg/ml, range 2.7-12.8; p < 0.001). A correlation between serum and CSF NfL levels was found (r = 0.461, p = 0.023), whereas no significant association was observed between NfL levels and clinical, MRI/CSF inflammatory burden, and antibody type. In the 13 available follow-up samples, correlation between disease activity and NfL values was also observed. In conclusion, NfL levels are significantly increased in the serum of patients with antibody-mediated encephalitis, independently of the MRI/CSF inflammatory profile. These findings support the presence of ongoing axonal damage and suggest the co-occurrence of different mechanisms for neuronal/axonal involvement in antibody-associated CNS syndromes.

Entities:  

Keywords:  Autoimmune encephalitis; CASPR2; LGI1; NMDAR; Neurofilament light chain; NfL

Year:  2019        PMID: 30944980     DOI: 10.1007/s00415-019-09306-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

1.  Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity.

Authors:  R Velasco; A A Argyriou; C Marco; S Mariotto; A Stradella; J Hernández; S Pernas; S Ferrari; J Bruna
Journal:  J Neurol       Date:  2022-09-12       Impact factor: 6.682

2.  Nervous system: subclinical target of SARS-CoV-2 infection.

Authors:  Sara Mariotto; Alessia Savoldi; Katia Donadello; Serena Zanzoni; Silvia Bozzetti; Sara Carta; Cecilia Zivelonghi; Daniela Alberti; Francesco Piraino; Pietro Minuz; Domenico Girelli; Ernesto Crisafulli; Simone Romano; Denise Marcon; Giacomo Marchi; Leonardo Gottin; Enrico Polati; Paolo Zanatta; Salvatore Monaco; Evelina Tacconelli; Sergio Ferrari
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-06-23       Impact factor: 10.154

3.  CSF and Serum Biomarkers of Cerebral Damage in Autoimmune Epilepsy.

Authors:  Robert Daniel Nass; Katja Akgün; Karmele Olaciregui Dague; Christian Erich Elger; Heinz Reichmann; Tjalf Ziemssen; Rainer Surges
Journal:  Front Neurol       Date:  2021-04-16       Impact factor: 4.003

4.  CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study.

Authors:  Mette Scheller Nissen; Matias Ryding; Anna Christine Nilsson; Jonna Skov Madsen; Dorte Aalund Olsen; Ulrich Halekoh; Magnus Lydolph; Zsolt Illes; Morten Blaabjerg
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

5.  Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis.

Authors:  Isabelle Quadrio; Virginie Desestret; Pierre Lardeux; Anthony Fourier; Elise Peter; Aline Dorey; Sergio Muñiz-Castrillo; Alberto Vogrig; Géraldine Picard; Véronique Rogemond; Mathieu Verdurand; Maité Formaglio; Bastien Joubert; Caroline Froment Tilikete; Jérôme Honnorat
Journal:  J Neurol       Date:  2021-06-08       Impact factor: 4.849

6.  Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis.

Authors:  Jasmini Alagaratnam; Sophia von Widekind; Davide De Francesco; Jonathan Underwood; Paul Edison; Alan Winston; Henrik Zetterberg; Sarah Fidler
Journal:  BMJ Neurol Open       Date:  2021-06-16

7.  Circulating Neurofilament Light Chain Is Associated With Survival After Pediatric Cardiac Arrest.

Authors:  Matthew P Kirschen; Nadir Yehya; Kathryn Graham; Todd Kilbaugh; Robert A Berg; Alexis Topjian; Ramon Diaz-Arrastia
Journal:  Pediatr Crit Care Med       Date:  2020-07       Impact factor: 3.971

8.  Serum neurofilament light chain withstands delayed freezing and repeated thawing.

Authors:  Patrick Altmann; Fritz Leutmezer; Heidemarie Zach; Raphael Wurm; Miranda Stattmann; Markus Ponleitner; Axel Petzold; Henrik Zetterberg; Thomas Berger; Paulus Rommer; Gabriel Bsteh
Journal:  Sci Rep       Date:  2020-11-17       Impact factor: 4.379

9.  Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae?

Authors:  Silvia Bozzetti; Sergio Ferrari; Serena Zanzoni; Daniela Alberti; Michele Braggio; Sara Carta; Francesco Piraino; Daniele Gabbiani; Domenico Girelli; Riccardo Nocini; Salvatore Monaco; Ernesto Crisafulli; Sara Mariotto
Journal:  Immunol Res       Date:  2021-08-07       Impact factor: 2.829

10.  Chronic fatigue syndrome: an emerging sequela in COVID-19 survivors?

Authors:  Elisa Mantovani; Sara Mariotto; Daniele Gabbiani; Gianluigi Dorelli; Silvia Bozzetti; Angela Federico; Serena Zanzoni; Domenico Girelli; Ernesto Crisafulli; Sergio Ferrari; Stefano Tamburin
Journal:  J Neurovirol       Date:  2021-08-02       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.